Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_assertion evidence source_evidence_literature NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_assertion SIO_000772 21245420 NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_assertion wasDerivedFrom befree-20150227 NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_assertion wasGeneratedBy ECO_0000203 NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- befree-20150227 importedOn "2015-02-27" NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.